Impact of belatacept conversion on kidney transplant function, histology, and gene expression - a single-center study.
belatacept
calcineurin inhibitors
immunosuppression
immunosuppression clinical
kidney clinical
molecular diagnostics
novel immunosuppressants
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
04
05
2020
revised:
28
05
2020
accepted:
07
08
2020
pubmed:
14
8
2020
medline:
25
6
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Prior studies on belatacept conversion from calcineurin inhibitor (CNI) have been limited by an absence of postconversion surveillance biopsies that could underestimate subclinical rejection, or a case-controlled design. A total of 53 adult patients with allograft dysfunction underwent belatacept conversion (median: 6 months) post-transplant. At a median follow-up = 2.5 years, patient survival was 94% with a death-censored graft survival of 85%. Seven (13%) patients had acute rejection (including 3 subclinical) at median 6 months postconversion. Overall, eGFR improved (P = <0.001) from baseline = 31±15 to 40.2 ± 17.6 ml/min/1.73m
Substances chimiques
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1458-1471Informations de copyright
© 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Références
Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011; 6: 430.
Grinyó JM, Del Carmen Rial M, Alberu J, et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Am J Kidney Dis 2016; 69: 587.
Gupta G, Regmi A, Kumar D, et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. Am J Transplant 2015; 15: 2726.
Le Meur Y, Aulagnon F, Bertrand D, et al. Effect of an early switch to belatacept among CNI-intolerant graft recipients of kidneys from extended criteria donors. Am J Transplant 2015; 16: 2181.
Brakemeier S, Kannenkeril D, Dürr M, et al. Experience with belatacept rescue therapy in kidney transplant recipients. Transpl Int 2016; 29: 1184.
Wojciechowski D, Chandran S, Vincenti F. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients. Clin Transplant 2017; 31: e12930.
Bertrand D, Cheddani L, Etienne I, et al. Belatacept rescue therapy in kidney transplant recipients with vascular lesions: a case control study. Am J Transplant 2017; 17: 2937.
Nair V, Liriano-Ward L, Kent R, et al. Early conversion to belatacept after renal transplantation. Clin Transplant. 2017; 31: e12951.
Schulte K, Vollmer C, Klasen V, et al. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism. J Nephrol 2017; 30: 607.
Abdelwahab Elhamahmi D, Heilman RL, Smith B, Huskey J, Khamash H, Kaplan B. Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate. Transplantation 2018; 102: 478.
Darres A, Ulloa C, Brakemeier S, et al. Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study. Transplantation 2018; 102: 1545.
Malvezzi P, Fischman C, Rigault G, et al. Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol. Transpl Immunol. 2019; 56: 101207.
Ulloa CE, Anglicheau D, Snanoudj R, et al. Conversion from calcineurin inhibitors to belatacept in HLA- sensitized kidney-transplant recipients with low-level donor specific antibodies. Transplantation 2019; 103: 2150.
Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272.
Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant. 2007; 7: 2114.
Halloran PF, Reeve J, Akalin E, et al. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. Am J Transplant 2017; 17: 2851.
Halloran PF, Merino Lopez M, Barreto Pereira A. Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants. Am J Transplant 2016; 16: 908.
Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 2215.
Einecke G, Broderick G, Sis B, Halloran PF. Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant 2007; 7: 1121.
Einecke G, Kayser D, Vanslambrouck JM, et al. Loss of solute carriers in T cell-mediated rejection in mouse and human kidneys: an active epithelial injury-repair response. Am J Transplant 2010; 10: 2241.
Famulski KS, de Freitas DG, Kreepala C, et al. Molecular phenotypes of acute kidney injury in kidney transplants. J Am Soc Nephrol 2012; 23: 948.
Kumar D, LeCorchick S, Gupta G. Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants. Frontiers in medicine. 2017; 4: 60.
Grinyo JM, Del Carmen Rial M, Alberu J, et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Am J Kidney Dis 2017; 69: 587.
Grinyo J, Alberu J, Contieri FL, et al. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int 2012; 25: 1059.
Loupy A, Aubert O, Orandi BJ, et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 2019; 366: l4923.
Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466.
Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
Brocker V, Schubert V, Scheffner I, et al. Arteriolar lesions in renal transplant biopsies: prevalence, progression, and clinical significance. The American journal of pathology. 2012; 180: 1852.
Einecke G, Reeve J, Halloran PF. Hyalinosis Lesions in Renal Transplant Biopsies: Time-Dependent Complexity of Interpretation. Am J Transplant 2017; 17: 1346.
Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635.
Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698.
Maluf DG, Dumur CI, Suh JL, et al. Evaluation of molecular profiles in calcineurin inhibitor toxicity post-kidney transplant: input to chronic allograft dysfunction. Am J Transplant 2014; 14: 1152.
Vitalone MJ, Ganguly B, Hsieh S, et al. Transcriptional profiling of belatacept and calcineurin inhibitor therapy in renal allograft recipients. Am J Transplant 2014; 14: 1912.
Jeffery M, Venner KSF, Reeve Jeff, Chang Jessica, Halloran Philip F. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight 2016; 1: e85323.